Gilead Sciences, Inc (GILD) Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Gilead Sciences, Inc (NASDAQ: GILD) FY 2026 Other Release

Newsdesk: